* Trodelvy/Keytruda patients had 11.2 months progression-free survival vs 7.8 months for chemotherapy/Keytruda * ASCO says Trodelvy/Keytruda likely to become standard of care * Patients still being followed to see if combination extends survival By Deena Beasley May 31 (Reuters) - Gilead Sciences' ( GILD ) Trodelvy in combination with Merck's ( MRK ) blockbuster immunotherapy Keytruda lowered the risk...

ROME (Reuters) -Europe's largest film studio Cinecitta is aiming to re-launch Italy as a movie powerhouse, even as U.S. President Donald Trump's proposed tariffs on foreign productions cast a shadow over the film industry globally. Cinecitta, the homonymous company that manages Rome's historic film studio, approved a five-year plan this week backed by the EU's post-COVID Recovery Fund, which includes...

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

May 31 (Reuters) - An experimental treatment by Pfizer ( PFE ) and Arvinas ( ARVN ) delayed progression of breast cancer by more than three months compared to AstraZeneca's ( AZN ) Faslodex in patients with a specific gene mutation, according to trial results announced on Saturday. The findings were presented in Chicago at the annual meeting of the...